Dr Anna Kalff is a clinical haematologist based at Cabrini and The Alfred Hospital, and a clinician-researcher within the Myeloma Research Group (MRG), Monash University. She manages/treats patients with malignant haematological disorders including myeloma, amyloidosis, lymphoma, leukaemia, myelodysplastic and myeloproliferative conditions, as well as a range of benign haematological disorders.
Dr Kalff graduated with honours from Monash University in 2001 and completed her dual clinical and laboratory training in Haematology at The Alfred and Royal Melbourne Hospitals (FRACP and FRCPA). She was the inaugural Merrin Foundation Myeloma Fellow at The Alfred Hospital. She was awarded her PhD in 2021: her research focused on the identification of predictive response biomarkers and the development of novel early phase drug combinations in both the maintenance and relapsed myeloma disease settings.
Dr Kalff is a member of the myeloma/lymphoma craft groups at the Alfred where her clinical role involves the care of both outpatient and inpatients (including patients undergoing CAR-T, T-cell engaging (TCE) therapy and autologous stem cell transplant). She is an investigator for numerous investigator-initiated and sponsored myeloma clinical trials (including CAR-T and TCE therapies) as well as CAR-T trials in auto-immune disease.
Dr Kalff is a member of the Myeloma Australia Medical Scientific Advisory Group (MSAG), The ALLG myeloma working party, and her research has been published in peer review journals and presented at both national and international meetings. She has received awards from the American Society of Haematology (ASH), International Myeloma Society (IMS), Myeloma Australia (MFA) and Haematology Society of Australia and New Zealand (HSANZ). She is also a member of the Snowdome Foundation Grants Committee.